InvestorsObserver
Sign Up Login

ADMP Adamis Pharmaceuticl

$0.45 $0.00 (-1.01%)
Add to Watchlist Compare
Overall

ADMP Stock Analysis Overview

What this means: InvestorsObserver gives Adamis Pharmaceuticl (ADMP) an overall rank of 31, which is below average. Adamis Pharmaceuticl is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 31 means that 69% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

ADMP Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

ADMP Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

ADMP Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

ADMP Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

ADMP Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

ADMP Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

ADMP Stock Analysis Overview

What this means: InvestorsObserver gives Adamis Pharmaceuticl (ADMP) an overall rank of 31, which is below average. Adamis Pharmaceuticl is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 31 means that 69% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full ADMP report

ADMP Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

ADMP Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

ADMP Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

ADMP Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

ADMP Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

ADMP Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Adamis Pharmaceuticl (ADMP) Analyst Forecast

ADMP Price, Volume, Earnings, and Dividend Date

  • Last Price $0.45
  • Previous Close $0.45
  • Change $0.00
  • Open $0.44
  • Volume 624,105
  • Avg. Volume (100-day) 762,331
  • Market Cap 67,379,969
  • Days Range 0.4212 - 0.48
  • 52-week Range 0.31 - 1.48
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS —
  • Earnings Date 08/15/22
  • Sector Healthcare
  • Industry Drug Manufacturers - Specialty & Generic
  • Avg. Analyst Rec. Premium
  • Beta 1.037
  • PEG Ratio —

Adamis Pharmaceuticl (ADMP) Company Description

Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.

Adamis Pharmaceuticl (ADMP) Stock Chart

View Interactive ADMP chart

My Watchlists

Follow Your Favorite Stocks

Top Stocks in Drug Manufacturers - Specialty & Generic

Company Price
Assertio Therapeutics Inc (ASRT) (ASRT) $2.89
Optinose Inc (OPTN) (OPTN) $3.53
Dynavax Technologies (DVAX) (DVAX) $12.50
Cardiol Therapeutics (CRDL) (CRDL) $1.63
Catalent Inc (CTLT) (CTLT) $110.87
Painreform Ltd (PRFX) (PRFX) $1.06
Intercure Ltd (INCR) (INCR) $6.05
Evolus Inc (EOLS) (EOLS) $12.83
Harrow Health Inc (HROW) (HROW) $7.38
Deciphera Pharmaceuticals Inc (DCPH) (DCPH) $13.73